Embecta Corp. (EMBC)
Embecta Corp. (EMBC) Stock Price, Analysis & Data
| Bid | 3.56 |
| Market Cap | 269.13M |
| Revenue (ttm) | 1.02B |
| Net Income (ttm) | 87.5M |
| Beta | 0.79 |
| EPS (ttm) | 1.47 |
| PE Ratio (ttm) | 3.23 |
| Forward PE | 2.7 |
| P/B (ttm) | -0.44 |
| P/S (ttm) | 0.26 |
| Earnings Date | Nov 25, 2026 |
| Ask | 5.05 |
| Volume | 1,592,817 |
| Avg. Volume (20D) | 2,092,317 |
| Open | 4.99 |
| Previous Close | 4.88 |
| Day's Range | 4.63 - 5.00 |
| 52-Week Range | 2.77 - 15.55 |
| Analyst | Hold |
| Price Target | 4 (-15.79%) |
| Dividends | $0.04 (0.82%) |
| Ex-Dividend Date | Aug 27, 2026 |
About EMBC
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, In...
Financial Performance
In 2025, Embecta's revenue was 1.08B, a decrease of -3.8% compared to the previous year's 1.12B. Earnings were 95.4M, an increase of 21.84%.
Financial StatementsAnalyst Forecast
According to 2 analyst ratings, the average rating for EMBC stock is "Hold". The 12-month stock price forecast is 4, which is downside of 15.79% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
